On July 29, the Wuhan Federation of Industry and Commerce, Wuhan Enterprises Federation and Wuhan Entrepreneurs Association jointly released the 2019 ranking lists of “Top 100 Private Enterprises in Wuhan” and “Top 100 Private Manufacturing Enterprises in Wuhan.” The minimum revenue of those listed among the “Top 100 Private Enterprises in Wuhan” is 1.278 billion yuan, increasing by 34.38% over the previous year. Grand Pharma (China) Co., Ltd. (hereinafter “Grand Pharma”), a subsidiary of China Grand Enterprises, Inc., ranks 32th on the list of “Top 100 Private Enterprises in Wuhan” and 6th on the list of “Top 100 Private Manufacturing Enterprises in Wuhan.”

The same day, the ranking list of the 2019 (first) Hubei Best Listed Companies Awards, sponsored by Hubei Daily Media Group and organized by the Pivot magazine and the Pivot economic journal, was unveiled. Grand Pharma was awarded the prize for the Listed Company with the Greatest Social Responsibility in Hubei Province.

In the past year, facing a challenging, complicated external environment and great pressure from transformation and upgrading, Grand Pharma calmly addressed various risks and challenges, focused on seeking self-improvement, and constantly improved its core competitiveness, demonstrating a continuous trend of positive development and realizing remarkable achievements in business. It has become one of the most representative private enterprises with the greatest potential and highest-quality development in Wuhan. The continuous rise of its place on the ranking list of private enterprises in Wuhan and its winning of the prize for the Listed Company with the Greatest Social Responsibility in Hubei Province showcased the wide recognition from the whole of society for Grand Pharma’s overall strength and corporate development as well as its in-depth exploration and execution of social responsibility. This also proved the positive contributions made by Grand Pharma to increasing profits, creating job opportunities, and paying taxes as well as to the environment, consumers, society and other aspects.

Next, Grand Pharma will continue focusing on technological innovation, management innovation and business mode innovation to turn comparative advantages into development advantages. With a cheerful spirit and strong determination, it will adhere to sustainable, steady high-quality development through continuous innovation.